Log in
Lost password
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nasdaq  >  Echo Therapeutics Inc    ECTE   US27876L2060

News SummaryMost relevantAll newsSector news 

ECHO THERAPEUTICS : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)

07/16/2014 | 04:54pm US/Eastern

Item 1.01 Entry into a Material Definitive Agreement.

The information set forth in Item 5.02 is incorporated by reference into this Item 1.01.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors;

           Appointment of Certain Officers; Compensatory Arrangements of Certain

Appointment of Certain Officers

On July 10, 2014, the Board of Directors (the "Board") of Echo Therapeutics, Inc. ("Echo" or the "Company") appointed Charles T. Bernhardt to serve as Interim Chief Financial Officer of Echo, effective July 16, 2014. Mr. Bernhardt, age 53, is a Certified Public Accountant who most recently served as Chief Financial Officer and Chief Accounting Officer for publicly traded Hemispherx Biopharma, Inc. from 2009 through 2013, at which an excess of $60 million was raised during his tenure. Mr. Bernhardt attained an undergraduate in Accountancy from Villanova University and received a Masters' Degree in Business Administration from West Chester University of Pennsylvania. He was formerly the Director of Accounting for Healthcare Division of Thomson Reuters, where he was responsible for their accounting operations and shared financial services for the Healthcare and Scientific Divisions from 2006 to 2008. He was also a Regional Controller for Comcast Cable during 1999 to 2002, Director of Finance for TelAmerica Media from 2003 to 2006, and earlier in his career a member of the Internal Audit management teams for American Stores Corporation and ICI Americas/Zeneca (currently AstraZeneca Pharmaceuticals). In 1986, he became a C.P.A. licensed in Pennsylvania and New Jersey while with public accounting's "Big Four" firm of KPMG.

On July 16, 2014, Echo and Mr. Bernhardt executed an offer letter pursuant to which Mr. Bernhardt will serve as the Interim Chief Financial Officer of Echo (the "Agreement"). Echo has the right to terminate the Agreement, at any time, with or without cause and with or without notice. Echo will pay Mr. Bernhardt an annual salary of $220,000 and he is entitled to participate in and receive benefits under the Company's health and dental insurance plans. Mr. Bernhardt did not receive an equity grant pursuant to the Agreement.

There are no other arrangements or understandings between Mr. Bernhardt and any other persons pursuant to which he was appointed as Interim Chief Financial Officer of Echo. There are also no family relationships between Mr. Bernhardt and any director or executive officer of Echo and Mr. Bernhardt has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

The description of the material terms of the Agreement is qualified in its entirety by reference to the full text of the Agreement which is attached as Exhibit 10.1 and is incorporated herein by reference.

                 Item 9.01.  Financial Statements and Exhibits.

The Exhibits listed in the Exhibit Index immediately preceding such Exhibits are filed with or incorporated by reference in this report.


React to this article
04/16 ECHO THERAPEUTICS : Results of Operations and Financial Condition, Financial Sta..
04/15 ECHO THERAPEUTICS : Non-Reliance on Previous Financials, Audits or Interim Revie..
02/18 ECHO THERAPEUTICS : Entry into a Material Definitive Agreement, Unregistered Sal..
02/05 ECHO THERAPEUTICS : Changes in Registrant's Certifying Accountant (form 8-K)
02/04 ECHO THERAPEUTICS : Notice of Delisting or Failure to Satisfy a Continued Listin..
01/22 ECHO THERAPEUTICS : and Medical Technologies Innovation Asia Re-affirm Operation..
01/03 ECHO THERAPEUTICS : appoints Alan Schoenbart as chief financial officer
2014 ECHO THERAPEUTICS : Appoints Alan W. Schoenbart as Chief Financial Officer
2014 ECHO THERAPEUTICS : Appoints Alan W. Schoenbart as Chief Financial Officer
2014 ECHO THERAPEUTICS : Entry into a Material Definitive Agreement, Change in Direct..